China Lists PVH Group and Illumina as Unreliable Entities with Far-Reaching Implications
On February 4, China announced that it has included the American PVH Group and Illumina, Inc. on its unreliable entity list. This decision has garnered significant attention, signaling escalating tensions in Sino-U.S. trade relations.
The announcement stated that both companies violated normal market trading principles, disrupted regular transactions with Chinese enterprises, and adopted discriminatory measures against them, severely harming the legitimate rights and interests of Chinese businesses. The mechanism for the unreliable entity list will take corresponding actions against these entities in accordance with relevant laws and regulations to safeguard the legitimate interests of Chinese enterprises.
The announcement emphasizes that the relevant measures will take effect immediately and any unspecified matters will be executed according to the Regulations on Unreliable Entities. This action is viewed as an important step by China in responding to external pressures and protecting its market.
In the context of global economic integration, this move could have profound implications for business relations between China and the U.S., potentially prompting other countries to reassess their cooperative ties with China. As the international market environment evolves, companies need to closely monitor policy developments to navigate potential challenges and opportunities.
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
关于全面排查下架易制毒及易制爆产品信息的公告 Announcement on the Comprehensive Review and Removal of Product Information Related to Precursor and Explosive Precursor Chemicals
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
The FDA Officially Blesses AI for Liver Drug Development
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
U.S. Delays Mandatory GRAS Notification Proposal, Pushing Food-Additive Overhaul to Year-End
-
South Korea and Japan Launch Energy Supply Chain Cooperation as Hormuz Risks Grow
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
Recommend Reading
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
FDA Warning Letters Put GMP Back in Focus
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
January 15 Isopropanol Market Trend Upward in China
-
Premium Global Chemical Sourcing Requests (9-12Apr, 2026)
-
On January 15, China's titanium dioxide market remains firm and upward
-
Premium Global Chemical Sourcing Requests (10-14 Nov 2025)
-
Polyethylene Has Risen Strongly Since January